SMTI · Sanara MedTech Inc.

Sanara MedTech reported strong first quarter 2026 results, with net revenue increasing 19% year-over-year to $27.8 million, driven by a 21% increase in soft tissue repair product sales, partially offset by a slight decline in bone fusion products. Gross margin improved to 93% from 92%, reflecting favorable product mix. Operating income rose to $2.6 million from $0.8 million, as operating expenses grew at a slower pace (12%) than revenue. The company achieved GAAP net profitability from continuing operations of $0.4 million ($0.04 per diluted share), compared to a net loss of $0.6 million in the prior year quarter. Adjusted EBITDA increased 58% to $4.3 million. Management attributed the results to strong execution in the surgical market, expansion of the sales team to 43 representatives, and increased market penetration. The company reaffirmed its full-year 2026 revenue guidance of $116-$121 million (13%-17% growth) and provided Q2 2026 guidance of $28.5-$29.5 million (10%-14% growth). Cash and equivalents stood at $13.6 million with long-term debt of $46.2 million as of March 31, 2026.